8-KOther EventsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Aug 14, 2007)

Filed August 14, 2007For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 13, 2007, detailing two significant events that occurred in early August. First, the company announced on August 8th that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for rilonacept, a treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), and has granted it priority review status. This signifies a critical step towards potential market approval for this novel IL-1 Trap therapy. Furthermore, on August 13th, Regeneron reported receiving a $20 million milestone payment from Bayer HealthCare. This payment was triggered by the dosing of the first patient in a Phase 3 study for VEGF Trap-Eye, a treatment candidate for neovascular age-related macular degeneration (wet AMD). These developments highlight progress in both late-stage clinical development and regulatory review for key pipeline assets.

Key Highlights

  • 1FDA accepted BLA for rilonacept (IL-1 Trap) for CAPS and granted Priority Review.
  • 2Rilonacept is being investigated for long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).
  • 3Received a $20 million milestone payment from Bayer HealthCare.
  • 4Milestone payment was triggered by the first patient dosed in the Phase 3 study of VEGF Trap-Eye.
  • 5VEGF Trap-Eye is being studied for the neovascular form of age-related macular degeneration (wet AMD).

Frequently Asked Questions

Rilonacept, also known as the IL-1 Trap, is a drug candidate developed by Regeneron Pharmaceuticals. The company announced that its Biologics License Application (BLA) for rilonacept has been accepted by the FDA with priority review for the long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).

Priority review status means the FDA has determined that the drug's potential to be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition may be greater than approved therapies. This status typically leads to an expedited review process by the FDA, potentially shortening the time to market approval.

VEGF Trap-Eye is another drug candidate from Regeneron, being developed in collaboration with Bayer HealthCare. The 8-K filing indicates that the first patient has been dosed in a Phase 3 study for VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD). This marks a significant advancement into late-stage clinical trials for this indication.

Regeneron received a $20 million milestone payment from Bayer HealthCare upon the dosing of the first patient in the Phase 3 study of VEGF Trap-Eye. This payment represents a significant influx of capital for Regeneron, reflecting progress in the development of their pipeline and contributing to the company's financial resources.